SafeShot pulls in $9M to develop better prefilled syringes

SafeShot Technologies in California has raised $9 million to develop sterile, prefilled, next-generation syringes.

The med tech startup declined to disclose the investors behind the round. But the total funding includes $6 million in new financing, plus $3 million it nailed down a little more than a year ago. Prefilled syringes are basic medical devices, but SafeShot said it sees a market opportunity in the wake of safety concerns over compounders, which prepare custom doses in syringes and other devices.

SafeShot said it will address safety worries by "building a highest-quality, fully compliant syringe filling capability, leveraging its technology and focusing on underserved points of care."

The company has taken a number of steps to adjust to its new market focus. It's now part of the Reprise Technologies medical device incubator in Menlo Park, CA, for example. And it has brought on new executive talent.

Still, even prefilled syringes aren't completely protected from safety concerns. Last November, Italy's Bracco Diagnostics launched a Class I recall of its Isovue prefilled power injector syringes because they had visible particles inside. The concern was that the tainted products could cause strokes.

- read the release

Suggested Articles

Dexcom received a new European approval for its wearable continuous glucose monitor in pregnant women across Type 1, Type 2 and gestational diabetes.

Infectious disease blood tester Karius has raised $165 million led by SoftBank’s Vision Fund 2, the Japanese conglomerate’s sequel to its VC megafund.

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.